Board Elections 2025
Candidates for Secretary
Camille Cohen, MD, PhD
I am a nephrologist and Associate Professor in Paris with a long-standing commitment to monoclonal gammopathies of renal significance (MGRS). Trained under the mentorship of Professors Frank Bridoux and Jean-Paul Fermand, I contributed early to pivotal clinical studies refining the characterization of Randall-type monoclonal immunoglobulin deposition disease and other MGRS entities.
After a PhD in renal biology and two postdoctoral fellowships in Paris and Edinburgh, I established my own research group at INSERM U1149 dedicated to understanding the renal consequences of monoclonal immunoglobulin deposition. My laboratory focuses particularly on the role of cellular senescence and microenvironmental interactions in lesion development. Alongside my clinical practice at Hôpital Bichat and Saint Louis, I coordinate the French certified training program on MGCS and contribute to European consensus efforts on MGRS.
Paolo Milani, MD, PhD
Paolo Milani, MD, PhD, is Assistant Professor in Clinical Chemistry at the University of Pavia. He serves as a consultant at the Amyloidosis Research and Treatment Center at the Foundation IRCCS Policlinico San Matteo in Pavia, Italy—the national referral center for systemic amyloidosis and other monoclonal gammopathy of clinical significance. From 2020 to 2022, he was a Member at Large on the Board of Directors of the International Society of Amyloidosis.
Dr. Milani's research centers on plasma cell dyscrasias, particularly light-chain (AL) amyloidosis, aiming to enhance diagnosis, treatment, and management. He leads clinical trials at the Pavia Center, including a Phase II study on daratumumab and pomalidomide for relapsed AL amyloidosis (AIFA-funded) and the Italian Transthyretin Amyloidosis Web Network (funded by Global Bridges–Mayo Clinic). He is also partecipating in all the other clinical trials in the field of systemic amyloidosis. He is leading of different international collaborative studies regarding AL amyloidosis and also the international data collection regarding light chain deposition disease patients.
In the lab, he applies mass spectrometry to evaluate monoclonal proteins, improving diagnostic accuracy for plasma cell dyscrasias like amyloidosis. He holds an MD (2010), postgraduate in Internal Medicine (2016), and PhD in Experimental Medicine (2018) from Pavia, with a research fellow appointment at Mayo Clinic.
Vaishali Sanchorawala, MD
Dr. Vaishali Sanchorawala is the Professor of Medicine and Director of the Amyloidosis Center of Boston University School of Medicine and Boston Medical Center. She has been one of the pioneers in the field of clinical research in AL amyloidosis. Her work in the treatment of AL amyloidosis has been published in many peer-reviewed journals, which has resulted in the evolution of the standard of care for these patients. She is currently heading several clinical trials in the treatment of AL amyloidosis. She serves on the executive steering committee of the Amyloidosis Research Consortium and as an associate editor of Amyloid, Journal of Protein Folding Disorders. She has served on the board of the International Society of Amyloidosis as secretary from 2020-2022. She has helped to create and cultivate the next generation of physician-scientists in the area of clinical research in AL amyloidosis.
Candidates for Treasurer
Nelson Leung, MD
Nattawat Klomjit, MD
Dr. Nattawat Klomjit graduated magna cum laude from the Faculty of Medicine, Siriraj Hospital, Mahidol University in Bangkok, Thailand, in 2011. He completed his internal medicine residency at the University of Hawaii, followed by a nephrology fellowship in the Division of Nephrology and Hypertension at the Mayo Clinic in Rochester, Minnesota, where he received the Outstanding Clinical Fellow Award. In 2021, he joined the Division of Nephrology and Hypertension at the University of Minnesota as an Assistant Professor of Medicine, where he provides comprehensive care for patients with a wide range of kidney diseases, with particular focus on monoclonal protein–related kidney diseases.
Dr. Klomjit’s research is dedicated to advancing the understanding and treatment of rare and complex kidney conditions. His work focuses on monoclonal gammopathy of renal significance (MGRS), glomerulonephritis, complement-mediated kidney diseases, thrombotic microangiopathy and kidney complications in cancer patients. He has authored more than 40 publications in leading journals. Some important publications include predictors of MGRS (PMID: 32747354), Mayo MGRS prediction tool (PMID: 40403931), drug-induced TMA (PMID: 37740927) and etc. He also serves on the Research and Position Statement Committee of the American Society of Onconephrology, and is an active member of both the International Kidney and Monoclonal Gammopathy (IKMG) Research Group and the United States Thrombotic Microangiopathy Alliance (USTMA). In addition, he serves as a site principal investigator for multiple nephrology clinical trials focusing on complement-mediated kidney diseases, and is an editorial board member of BMC Nephrology as well as an ad hoc reviewer for several high-impact journals.
Dr. Klomjit’s contributions to nephrology have been recognized with numerous honors, including the Excellence in Teaching Award from the Department of Medicine at the University of Minnesota (2023), Best Poster Presentation at the National Kidney Foundation Meeting (2023), and election as a Fellow of the American Society of Nephrology (2022).